<code id='AB2CFD08DC'></code><style id='AB2CFD08DC'></style>
      • <acronym id='AB2CFD08DC'></acronym>
      <center id='AB2CFD08DC'><center id='AB2CFD08DC'><tfoot id='AB2CFD08DC'></tfoot></center><abbr id='AB2CFD08DC'><dir id='AB2CFD08DC'><tfoot id='AB2CFD08DC'></tfoot><noframes id='AB2CFD08DC'>
      • <optgroup id='AB2CFD08DC'><strike id='AB2CFD08DC'><sup id='AB2CFD08DC'></sup></strike><code id='AB2CFD08DC'></code></optgroup>
        5. <b id='AB2CFD08DC'><label id='AB2CFD08DC'><select id='AB2CFD08DC'><dt id='AB2CFD08DC'><span id='AB2CFD08DC'></span></dt></select></label></b><u id='AB2CFD08DC'></u>
          <i id='AB2CFD08DC'><strike id='AB2CFD08DC'><tt id='AB2CFD08DC'><pre id='AB2CFD08DC'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / leisure time      
           
     
           
      
          leisure time 
           
      
           
      
           
       2025-09-28 00:02:56 
   
      
           
      
           
                        
          leisure time  
          
                                   
                 
                                      author：explore   
                                        
                                      
                                      Page View：41721
                                  
                                    
          
                                   
          Adam's take main illustration
          Molly Ferguson/STAT
          Biotech is awash in PIPEs.
          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.
          advertisement
          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          The creative science of coining drug names
                                
                            
          Next article：  
                                      
                                          Alkermes shareholders re
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles